Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients
Dateline City:
WHITEHOUSE STATION, N.J.
Phase 3 Clinical Trial Enrollment Scheduled to Start by the End of 2014
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the presentation of results from a Phase 2b clinical
trial evaluating the safety and efficacy of once-daily oral doravirine,
an investigational next-generation non-nucleoside reverse transcriptase
inhibitor (NNRTI), plus tenofov...
Source: Merck.com - Research and Development News - November 3, 2014 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news
FDA Updates Stribild Labeling
On August 28, 2014, FDA approved updates to the label for Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir 300 mg) fixed-dose combination tablets. The label was updated with efficacy, resistance, and safety data from two clinical trials; renal information; and drug interaction information.
The updated labeling for Stribild is available at the FDA website.
More information is available:
FDA: Press release
AIDSinfo: Patient fact sheet on Stribild (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - September 12, 2014 Category: Infectious Diseases Source Type: news
Travis Sherer: What are you excited about in the fight against HIV/AIDS?
Founded in 1982 in direct response to the AIDS epidemic, GLMA has long been involved in issues related to HIV and AIDS. Although progress has been challenging at times, there is a lot right now to be hopeful about. Significant advances in the treatment and prevention of HIV have led us to an exciting place where we are able to discuss the potential for an end to the epidemic. Condom use, antiretroviral therapies, microbicides, PreP (pre-exposure prophylaxis) and PEP (post-exposure prophylaxis) provide a wide range of tools available help prevent the transmission of HIV. Treatment as prevention is real and within our gra...
Source: PHRMA - September 10, 2014 Category: Pharmaceuticals Authors: Emily Source Type: news
Uganda: Aids Patients Reject Bitter ARVs
[Observer]The Uganda Coalition for Access to Essential Medicine (UCAEM) has asked government to withdraw and cease use of non-film coated tenofovir and lamivudine, dubbing the drug combination as notoriously bitter. (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - September 10, 2014 Category: Infectious Diseases Source Type: news
Long-term Exposure to Tenofovir and Renal Function in HIVLong-term Exposure to Tenofovir and Renal Function in HIV
Does long-term use of tenofovir disoproxil fumarate (TDF) in HIV treatment affect renal function? AIDS (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 8, 2014 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news
